Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | DRD4 | P21917 | 2/20 | 0.59 |
| ▸ | DRD3 | P35462 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7031018 | 1.00 | DRD2 (0.71) | DRD2CHRM2CHRM1CHRM3DRD4 | |
| SCHEMBL3732774 | 0.92 | DRD2 (0.85) | DRD2DRD4DRD3 | |
| SCHEMBL7026910 | 0.91 | DRD2 (0.84) | DRD2DRD4DRD3 | |
| SCHEMBL7022890 | 0.91 | DRD2 (0.84) | DRD2DRD4DRD3 | |
| SCHEMBL8892571 | 0.83 | DRD2 (0.82) | DRD2CHRM2CHRM1CHRM3DRD4 | |
| SCHEMBL3730004 | 0.83 | DRD2 (0.61) | DRD2CHRM2CHRM1CHRM3DRD4 | |
| SCHEMBL2020108 | 0.83 | DRD2 (0.69) | DRD2DRD4DRD3 | |
| SCHEMBL13042649 | 0.81 | DRD2 (0.70) | DRD2CHRM2CHRM1CHRM3DRD4 | |
| SCHEMBL3740505 | 0.81 | DRD2 (0.70) | DRD2CHRM2CHRM1CHRM3DRD4 | |
| SCHEMBL8164138 | 0.81 | DRD2 (0.50) | DRD2CHRM2CHRM1CHRM3DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1014986-B1 | A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2004-07-14 | — | — | EP | disclosed |
| EP-1021183-B1 | A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1014985-B1 | A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A H5-HT 1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2003-05-21 | — | — | EP | disclosed |
| US-6534652-B2 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxytryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | ASTRAZENECA AB (SE) | 2003-03-18 | — | — | US | disclosed |
| EP-0888319-B1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| EP-1000048-B1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| US-6410530-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2002-06-25 | — | — | US | disclosed |
| US-6410532-B2 | 8-(PIPERIDIN-4-YL- OR PIPERAZIN-1-YL)-2-SUBSTITUTED-TETRALIN DERIVATIVES; SELECTIVE EFFECT AT A SUBGROUP OF 5-HYDROXY-TRYPTAMINE RECEPTORS, H5-HT1B RECEPTORS (PREVIOUSLY 5-HT1D BETA); ANTAGONISTS; MOOD DISORDERS, ANTIANXIOLYTIC | ASTRAZENECA AB (SE) | 2002-06-25 | — | — | US | disclosed |
| US-20010051623-A1 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxytryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | US | disclosed |
| US-20010051626-A1 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxy-tryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | US | disclosed |
| US-6313118-B1 | HYDROXYTRYPTAMINE RECEPTOR ANTAGONISTS | ASTRA AKTIEBOLAG (SE) | 2001-11-06 | — | — | US | disclosed |
| EP-1149083-A1 | MORPHOLINOBENZAMIDE SALTS | AstraZeneca AB (SE) | 2001-10-31 | — | — | EP | disclosed |
| US-6291458-B1 | Morpholinobenzamide salts | ASTRAZENECA AB (SE) | 2001-09-18 | — | — | US | disclosed |
| US-6159972-A | Combination of a selective 5-HT1A antagonist and a selective ub. h5-HT.s1B antagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | disclosed |
| US-6159970-A | Combination of a monoamine oxidase inhibitor and a h5-HT1B antagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | disclosed |
| US-6159971-A | Combination of a 5-HT reuptake inhibitor and a h5-HT1B anatagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | disclosed |
| US-6124283-A | Substituted 1,2,3,4-tetrahydronaphthalene derivatives | ASTRA AKTIEBOLAG (SE) | 2000-09-26 | — | — | US | disclosed |
| WO-2000043378-A1 | NEW MORPHOLINOBENZAMIDE SALTS | ASTRAZENECA AB (SE) | 2000-07-27 | — | — | WO | disclosed |
| EP-1000048-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | Astra Aktiebolag (SE) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005134-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051623-A1 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxytryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | HTR1D, HTR1F, HTR2C | DRD2 49/4885CHRM2 80/4885CHRM1 59/4885 |
| US-20010051626-A1 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxy-tryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | HTR1D, HTR1F, HTR2C | DRD2 52/4885CHRM2 85/4885CHRM1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.